CAR-T cell therapy research

Treatment-free interval duration during T-cell engager conditioning shapes simulated T-cell exhaustion and post-transfer tumor control

This paper uses an agent-based model to simulate how different treatment-free intervals during T-cell engager exposure affect T cell exhaustion and tumor control in B-ALL.

CSF1R-CAR T cells induce CSF1R signalling and promote cancer cell growth

CSF1R-CAR T cells induce CSF1R signaling in THP1 cells, promoting their growth, highlighting an unintended effect of CAR therapy.

Physiologically-based pharmacokinetic model for CAR-T cells delivery and efficacy in solid tumors

The paper develops a physiologically based pharmacokinetic model to simulate CAR-T cell dynamics in solid tumors, showing vascular normalization improves efficacy and reduces required CAR-T doses.

High Precision Peptide-MHC Class I CARs Enhance In Vivo Killing ofTargeted CD8 T Cells to Prevent Type 1 Diabetes in Novel RIP-mOVA Model

This paper develops a peptide-MHC Class I CAR platform that enhances in vivo killing of antigen-specific CD8 T cells and prevents type 1 diabetes in a novel RIP-mOVA model.

Antigen-scaffolds drive preferential expansion of functional genetically engineered CAR and TCR T cells

This study develops antigen-scaffold technology to expand CAR and TCR T cells with improved functionality and efficacy.

Synthetic peptide hydrogels as a model of the bone marrow niche demonstrate efficacy of a combined CRISPR-CAR T-cell therapy for acute myeloid leukaemia

The paper develops a synthetic BM niche model to test CRISPR-CAR T-cell therapy for AML, showing its efficacy in a human-like environment.

Chimeric Antigen Receptors Transmit Piconewton Forces that are Coupled with T Cell Function

This study measures piconewton forces transmitted by CAR T cells to their targets and links force magnitude to T cell function and exhaustion.

Development of antigen-dextramers for detection and evaluation of CAR T cells

This paper develops antigen-dextramers to stain and functionally assess CAR T cells, showing they enable both detection and activation analysis with adjustable antigen density.

Enhancing the iNKT cell immunotherapy platform by combining optimised CAR endodomains with novel iNKT engagers

This study enhances iNKT cell immunotherapy by combining optimized CAR endodomains with novel iNKT-specific engagers to improve anti-myeloma activity.

Collagen-binding IL-12 expressing STEAP1 CAR-T cells reduce toxicity and eradicate mouse prostate cancer in combination with checkpoint inhibitors

Chimeric Antigen Receptors Transmit Co-stimulatory Domain Dependent Piconewton Forces to their Target

This study measures piconewton forces transmitted by CARs during antigen engagement, showing co-stimulatory domains are essential for force generation and early signaling.

CAR T-cells dysfunction in the central nervous system is mediated by BBB-induced activation-induced cell death

The paper investigates CAR T-cell dysfunction in the CNS, identifying BBB-induced activation-induced cell death as a mechanism of resistance.

Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells

This study develops anti-9G4 CAR-T and TCR-T cells to selectively target autoreactive B cells in SLE, reducing immunosuppression and cytokine toxicity.

Engineering human protein switches for functional control of CARs and transcription factors via oral drug administration

This paper describes the engineering of a molecular switch that controls CARs and transcription factors using an orally available drug, demonstrating tight regulation in vitro and in vivo.

Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response

This paper designs TCRs with ICOS to improve T cell therapy, showing durable anti-tumor effects and resistance to exhaustion in mice and humans.

RELB Reprograms Exhausted Tumor-Infiltrating Lymphocytes for Improved Adoptive Cell Therapy

This study identifies RELB as a key regulator that enhances TIL expansion and function, improving adoptive cell therapy for solid tumors.

A differentiated and durable allogeneic strategy applicable to cell therapies

This paper develops an allogeneic T cell therapy strategy using gene editing to reduce immune rejection and enable off-the-shelf use, showing comparable function to autologous cells.

An open CAR-T single-cell atlas to enable in-depth characterization and rational engineering of CAR-T products

The paper constructs a CAR-T cell functional atlas from over one million cells across 13 studies to link product composition with clinical response and identify sex- and age-dependent effects.

Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors

This study shows that disrupting autophagy in CAR-T cells enhances their metabolic activity and improves their ability to reject ovarian tumors in vivo.

Antigen receptor competition in CAR-TCR cells changes cytotoxicity outcomes upon spatial antigen separation

The paper investigates how spatial separation of antigens affects cytotoxicity in CAR-TCR cells by analyzing clonotype dynamics and functional TCR contributions.

Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy

This study uses base-editing to inactivate a missense mutation in A20ZF7, enhancing CAR-T cell efficacy by reducing exhaustion and improving anti-tumor responses.

Optimization of velocity receptor transduction in CAR T cells

This study optimizes velocity receptor (VR) transduction in CAR T cells by evaluating vector modifications and transduction efficiency, finding that VR5IL8 and VR5TNF perform best.

Differential effects of immobilized CCL21 and ICAM1 on TILs with distinct expansion properties

This study identifies markers distinguishing TIL expansion properties and develops SIN-based strategies to enhance expansion and activation of both low- and high-expanding TILs.

Integrated scFv identification and CAR T cell generation for AML targeting in vivo

This study integrates scFv development with CAR T cell generation to target CLL1-positive AML, showing effective tumor killing in vivo.

Base edited "universal" donor CAR T cell strategies for acute myeloid leukaemia

This study shows that base edited universal donor CAR T cells targeting multiple antigens can inhibit AML in mice, with combination therapies needed for heterogeneous disease.

Acquisition of an immunosuppressive microenvironment after CAR-T therapy drives T-cell dysfunction and resistance

This study shows that CAR-T therapy induces an immunosuppressive microenvironment, leading to T-cell dysfunction and resistance in B-ALL patients.

CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumors

This study develops N4CART cells targeting Nectin-4 that overcome resistance to EV in solid tumors and show safety by avoiding skin toxicity.

A Tonic Signaling Code Predicts CAR-T Cell Efficacy in Diffuse Midline Glioma

This study identifies tonic signaling as a key factor in CAR-T cell efficacy for diffuse midline glioma, showing that restrained tonic signaling improves therapeutic outcomes.

Hyper-migratory CAR T cells alleviate ovarian cancer metastatic burden and improve prognosis

This study shows hyper-migratory CAR T cells reduce ovarian cancer metastasis and improve survival in mice.

In vivo CRISPR screens identify key modifiers of CAR T cell function in myeloma

The paper uses in vivo CRISPR screens to identify genes affecting CAR T cell persistence and function in multiple myeloma, finding CDKN1B as a key regulator of late-stage CAR T cell fitness.